ResMed Inc. 10-Q Summary: Quarter Ended March 31, 2003
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing devices for sleep-disordered breathing (primarily obstructive sleep apnea). The reporting period covers the three and nine months ended March 31, 2003. Manufacturing operations are located in Australia, Germany, and the United States, with major distribution sites globally.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2003 | Nine Months Ended Mar 31, 2003 |
|---|---|---|
| Net Revenue | $68.996 million | $192.875 million |
| Gross Profit | $43.187 million | $122.723 million |
| Gross Margin | 62.6% | 63.6% |
| Operating Income | $17.106 million | $48.689 million |
| Net Income | $12.250 million | $32.205 million |
| Diluted EPS | $0.35 | $0.94 |
| Cash from Operations (9mo) | $37.137 million | |
| Cash & Equivalents (Mar 31, 2003) | $93.715 million | |
| Convertible Notes Outstanding | $113.250 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 31% ($16.2 million) for the quarter and 30% ($45.1 million) for the nine months compared to the prior year periods. Growth was driven by increased unit sales of flow generators and accessories, the acquisition of Servo Magnetics Inc. (SMI), and favorable foreign currency exchange rates.
- Margin Compression: Gross margin decreased slightly to 63% for the quarter (from 64%) and 64% for the nine months (from 65%). This was attributed to higher manufacturing costs due to a stronger Australian dollar and the inclusion of SMI's lower-margin motor sales.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 28% for the quarter and 31% for the nine months, driven by personnel increases, currency appreciation, and litigation costs. R&D expenses increased 34% for the quarter and 33% for the nine months due to new product development.
- Debt Reduction: The company repurchased $10.0 million face value of convertible subordinated notes during the nine-month period, recognizing a gain of $0.3 million.
Outlook, Risks, and Management Commentary
- Product Pipeline: Three of five in-process R&D projects from the MAP acquisition have been completed (Papillon mask, headgear, Magellan device). The standalone humidifier project is delayed, and the diagnostic device is expected to launch in calendar 2003.
- Legal Proceedings: ResMed settled a patent infringement lawsuit with Fisher & Paykel Healthcare in May 2003. Litigation with Respironics regarding mask patents continues, with no trial dates set. Management believes outcomes will not have a material adverse effect.
- Capital Allocation: The company is constructing a new manufacturing facility in Sydney, Australia, with estimated building costs of $32.0 million, funded by cash reserves and operations. A share repurchase program is active; 125,318 shares were repurchased in the nine months ended March 31, 2003.
- Risks: Key risks include foreign currency fluctuations (significant exposure to AUD and EUR), regulatory delays (specifically in Japan for the Autoset Spirit), competition, and reliance on third-party reimbursement.
Investor Verification Checklist
- Verify the status of the ongoing patent litigation with Respironics and potential financial exposure.
- Monitor the impact of the Australian dollar exchange rate on future gross margins, given the concentration of manufacturing costs in Australia.
- Confirm the timeline for the release of the remaining in-process R&D products (diagnostic device and standalone humidifier).
- Review the progress and cost overruns of the new Sydney manufacturing facility construction.
- Assess the integration performance of the Servo Magnetics Inc. (SMI) acquisition on overall margins.